Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism

[1]  M. Gatzoulis,et al.  Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. , 2008, International journal of cardiology.

[2]  B. Mulder,et al.  Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? , 2007, American heart journal.

[3]  P. Engelfriet,et al.  Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. , 2007, International journal of cardiology.

[4]  K. Dimopoulos,et al.  Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease , 2007, Heart.

[5]  B. Mulder,et al.  Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition. , 2007, Congenital heart disease.

[6]  P. Engelfriet,et al.  Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease , 2006, Heart.

[7]  F. Fedele,et al.  Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect , 2006, Heart.

[8]  R. Speich,et al.  Measurement of quality of life in pulmonary hypertension and its significance , 2006, European Respiratory Journal.

[9]  D. Cokkinos,et al.  Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study , 2006, Heart.

[10]  M. Humbert,et al.  Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. , 2006, Proceedings of the American Thoracic Society.

[11]  R. Speich,et al.  Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. , 2006, Chest.

[12]  M. Humbert,et al.  The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study , 2006, European Respiratory Journal.

[13]  S. Hammerschmidt,et al.  Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension , 2006, Respiration.

[14]  B. Mulder,et al.  Applicability of bosentan in Dutch patients with Eisenmenger syndrome: preliminary results on safety and exercise capacity. , 2006, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[15]  T. Welte,et al.  Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[16]  W. Klepetko,et al.  Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. , 2005, Chest.

[17]  D. Badesch,et al.  Evaluation and Management of the Patient with Pulmonary Arterial Hypertension , 2005, Annals of Internal Medicine.

[18]  D. Cokkinos,et al.  Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease , 2005, Heart.

[19]  K. Kerr,et al.  Chronic thromboembolic pulmonary hypertension. , 2004, Clinics in chest medicine.

[20]  D. Mccrory,et al.  Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.

[21]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[22]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[23]  M. Uematsu,et al.  Poor prognosis and related factors in adults with Eisenmenger syndrome. , 2002, American heart journal.

[24]  K. Kerr,et al.  Chronic thromboembolic pulmonary hypertension. , 2001, Clinics in chest medicine.

[25]  D L Sherrill,et al.  Reference equations for the six-minute walk in healthy adults. , 1998, American journal of respiratory and critical care medicine.

[26]  J. Widimský,et al.  Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. , 1982, Chest.

[27]  M. Gatzoulis,et al.  Double-Blind , Randomized , Placebo-Controlled Study Bosentan Therapy in Patients With Eisenmenger Syndrome : A Multicenter , 2006 .

[28]  A. Waggoner,et al.  Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. , 2002, The American journal of cardiology.

[29]  D. Mccrory,et al.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.